As the drug shortage crisis continues to spiral out of control, a potential solution comes to the forefront in the form of new bipartisan legislation: The Drug Shortage Prevention Act.
Perhaps it is a bit ironic, but just when new drug approvals by the Food and Drug Administration (FDA) hit a 7-year high, we seem to be battling record numbers of medication shortages.
The irony isn’t lost on U.S. Reps. John Carney (D-DE) and Larry Bucshon (R-IN), who this week introduced the Drug Shortage Prevention Act.
An excerpt from the announcement reads:
The legislation mandates expedited review of drugs vulnerable to the shortage in order to prevent shortages in the first place, and it requires FDA to use a more refined regulatory process that addresses manufacturing problems without instigating drug shortages. The bill also streamlines communications between FDA, manufacturers, distributors, providers, and patients to ensure that all parties have the information they need to act proactively—instead of reactively—to prevent shortages from occurring.
While we await the ultimate fate of the Drug Shortage Prevention Act, it’s important to stay abreast of the current situation.
A recent report by the University of Utah Drug Information Service revealed that 267 medications were subject to shortages in 2011, 56 more than in 2010.
The news could have been worse—the FDA took steps in 2011 to prevent some supply shortfalls by requiring manufacturers to report potential shortages in advance to the FDA. According to the University of Utah, the FDA’s actions may have prevented up to 100 additional shortages.
A recent shortage that gained significant media coverage was the Gaucher disease medication imiglucerase (Cerezyme). Genzyme’s key plant producing this agent was closed for viral decontamination in 2009, and Cerezyme had only been removed from the FDA’s list of medication supply problems in 2010 before being replaced on the list in September 2011.
Of all of the medications listed on the FDA’s Drug Shortage List (http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050792.htm), it seems sterile injectable products have been hardest hit.
According to an interview with the Associated Press, Erin Fox, PharmD, Director of the University’s Drug Information Service, the supply issues are caused by the need for manufacturers to shut down key production plants because of quality control problems. Additionally, consolidation of the generic drug industry has resulted in fewer manufacturers producing generic versions of similar products. The revenue generated by these medications may not be enough to retain manufacturers’ interest in expending resources on their production.
Hospitals have been greatly affected by the shortage. Dr. Fox points out that current shortages in sedatives like diazepam, midazolam, lorazepam, often used in surgery, along with shortages of the pain medication fentanyl, have created strain across the numerous departments within hospitals. Metronidazole, the mainstay of treatment for Clostridium difficile infection, is also on the shortage list.
The number of drugs on the shortage list has increased each of the last 5 years. In 2005, there were 61 drug shortages; in 2010 that number spiked to 178, according to Reps. Carney and Bucshon.
These shortages have disrupted chemotherapy regimens for cancer, surgical care, and infectious disease and pain management. Fortunately, suitable and available alternatives exist for a great many of these at-risk medications. But the bigger problem still looms as we await the fate of the Drug Shortage and Prevention Act.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen